North America Whole Exome Sequencing Market, By Component (Whole Exome Sequencing, Second-Generation Sequencing, and Third-Generation Sequencing), Product and Services (Systems, Kits and Services), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture & Animal Research, and Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
North America Whole Exome Sequencing Market Analysis and Insights
Increasing the preference of WES over whole-genome sequencing due to its low-cost sequencing capability are the major factors for drive the market growth in the forecast period. However, high instrument costs, the need for skilled professionals, and high reliance on grants and funds may hamper the future growth of whole exome sequencing market. Adoption of strategic alliances like partnerships and acquisitions by key market players act as opportunity for the growth of whole exome sequencing market.
Whole exome sequencing market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 22.0% in the forecast period of 2023 to 2030 and is expected to reach USD 2,192.73 million by 2030 from USD 435.97 million in 2022.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customized to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Millions, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Component (Whole Exome Sequencing, Second-Generation Sequencing, and Third-Generation Sequencing), Product and Services (Systems, Kits and Services), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture & Animal Research, and Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, and Integrated DNA Technologies, Inc.
|
Market Definition
Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, called WES. Whole-exome sequencing is a widely used whole exome sequencing (WES) method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, 1 making this method a cost-effective alternative to whole-genome sequencing
North America Whole Exome Sequencing Market Dynamics
Drivers
- Increasing Diagnostics Applications of Whole Exome Sequencing
There are over 7,000 identified rare diseases and approximately 80% are linked to genetic causes, diagnosing rare disease patients can often be challenging – resulting in lengthy, expensive, and emotional diagnostic odysseys.
Hence, diagnostic applications of WES is expected to propel the market size and is expected to act as driver for the global whole exome sequencing market in the forecast period.
- Growing Usage of Targeted Sequencing Methods
Next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors as genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer.
NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. The need to order multiple tests to identify the causative mutation is eliminated because NGS can assess multiple genes in a single assay.
Opportunity
- Increasing Product Launch in Recent Years
Market players are focusing on launch of new products in whole exome sequencing due to increasing demand for whole exome sequencing techniques. Advancement in the technology is helping the market players for multiple launches of products.
The product launches in the recent years have shown the potential of this technologies and the companies working on this market are trying to get more advanced product in the market which will act as opportunity for the market and will propel the market in forecast period.
Challenges/ Restraints
- Cyber Security Concern in Genomics
Software is known to contain vulnerabilities caused by imperfect code, misconfiguration among other and NGS-related software, used to operate sequencing and laboratory equipment or carry out the bioinformatics analyses, is no exception. Software vulnerabilities are exploited to gain unauthorised access to computer systems or networks, leak data, crash or otherwise disrupt various services.
These types of incidences about data breach and cyber threat associated with the whole exome sequencing is expected to impede the market growth in the forecast period.
- Lack of skilled professionals
The interpretation of whole-exome sequencing (WES) data requires expertise in genomic informatics and clinical medicine to ensure the accurate and safe reporting of findings. The first step of WES involves the acquisition of high-quality genomic DNA (gDNA) from biological samples, most commonly extracted from peripheral blood leukocytes. Professionals should have information about extraction of gDNA. In addition, the preparation of an exome enrichment library is required in WES which is not known to many healthcare specialists.
The professionals are lacking skills are not suitable for performing whole exome sequencing as the diagnostic samples of patients are of keen importance. The need for skilled healthcare has increased. Thus, the lack of skilled professionals to perform whole exome sequencing acts as challenge for the growth of the market.
Recent Development
- In March, Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in a single day. It is designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument. This has helped the company to make advancements in its product portfolio
North America Whole Exome Sequencing Scope and Market Size
North America whole exome sequencing market is segmented on the basis of component, product and service, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Component
- Whole Exome Sequencing
- Third-Generation Sequencing
On the basis of component, the North America whole exome sequencing market is segmented into whole exome sequencing and third-generation sequencing.
Product And Services
- Systems
- Kits
- Services
On the basis of product and service, the North America whole exome sequencing market is segmented into systems, kits, and services.
Application
- Diagnostics
- Drug Discovery and Development
- Personalized Medicine
- Agriculture & Animal Research
- Others
On the basis of application, the North America whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine, and others.
End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Laboratories
- Others
On the basis of end user, the North America whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
Distribution Channel
- Direct Trade
- Retail sales
- Others
On the basis of distribution channel, the North America n whole exome sequencing (WES) market is segmented into direct trade, retail sales, and others.
North America Whole Exome Sequencing Market Regional Level Analysis
The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user, and distribution channel.
The countries covered in the whole exome sequencing (WES) market report are the U.S., Canada, Mexico.
U.S. is expected to dominate the market due to the presence of key market players along the largest consumer market with high GDP. U.S. is expected to grow due to rise in technological advancement.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Whole Exome Sequencing Market Share Analysis
Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.
Some of the major companies which are dealing in the North America whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, and Integrated DNA Technologies, Inc., among others.
SKU-